eISSN: 1731-2531
ISSN: 1642-5758
Anaesthesiology Intensive Therapy
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees

Journal integrated with

integrated with publons
5/2021
vol. 53
 
Share:
Send email
Share:
abstract:
Original paper

Convalescent plasma for COVID-19 in the intensive care unit

Kazım Rollas
1
,
Ömer Emgin
1
,
Taner Çalışkan
1
,
Işıl K. Güldoğan
1
,
Çiler Zincircioğlu
1
,
Gürsel Ersan
2
,
İsa Sahar
1
,
Aykut Sarıtaş
1
,
Uğur Uzun
1
,
Nimet Senoğlu
1

  1. Department of Anaesthesiology Intensive Care, S.B.Ü. Tepecik Training and Research Hospital, İzmir, Turkey
  2. Department of Infectious Diseases and Clinical Microbiology, S.B.Ü. Tepecik Training and Research Hospital, İzmir, Turkey
Anaesthesiol Intensive Ther 2021; 53, 5: 398–402
DOI: https://doi.org/10.5114/ait.2021.111551
Online publish date: 2021/12/30
View full text Get citation
 
PlumX metrics:
Introduction
We aimed to investigate the clinical features and mortality of critically ill patients treated with convalescent plasma for COVID-19 in the intensive care unit (ICU).

Material and methods
We retrospectively collected clinical and laboratory data of COVID-19 patients treated in the ICU. The patients were divided into two groups: those who received convalescent plasma and those who did not. We evaluated changes in the laboratory parameters and PaO2/FiO2 of the patients in the convalescent plasma group on days 0, 7, and 14.

Results
A total of 188 patients were included, 89 of whom received convalescent plasma. There were no significant differences in length of hospitalization [median: 17 vs. 16 days, P = 0.13] or 28-day mortality between the two groups (59% vs. 65%, P = 0.38). The ICU stay of patients who received convalescent plasma was longer (P = 0.001). The dynamics of the laboratory parameters of 44 patients in the convalescent plasma group, who were still in intensive care on the 14th day, were analysed. There was no differences in CRP or PaO2/FiO2 on day 0, 7 or 14 (P = 0.12; P = 0.10, respectively).

Conclusions
Convalescent plasma treatment was not associated with shorter hospitalisation or lower mortality in patients diagnosed with COVID-19. However, the ICU stay was longer in patients who received convalescent plasma.

keywords:

immune plasma, COVID-19, pneumonia, mortality, intensive care
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.